Investor Backing & Capital Strength:
A large Series D round in February 2026 led by a top-tier investor at a unicorn valuation signals strong capital support. The new funding is described as runway for headcount, product development, and market expansion.
Strong Revenue Growth:
Company communications around the 2026 financing cite rapid year-over-year revenue gains. This momentum is positioned as evidence of increasing commercial adoption.
Market Expansion:
Public materials reference a growing base of hundreds of organizations and new health-system partnerships announced in 2026. Ongoing hiring and new launches in May 2026 indicate active go-to-market execution.
